Success Metrics

Completion Rate
0%(0/1)
Active Trials
5(83%)
Terminated
1(17%)

Phase Distribution

Ph phase_2
3
50%
Ph phase_3
2
33%
Ph not_applicable
1
17%

Phase Distribution

0

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
2(33.3%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

5

trials recruiting

Total Trials

6

all time

Status Distribution
Active(5)
Terminated(1)

Detailed Status

Recruiting5
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
5
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (50.0%)
Phase 32 (33.3%)
N/A1 (16.7%)

Trials by Status

recruiting583%
terminated117%

Recent Activity

5 active trials
Showing 5 of 6
recruitingnot_applicable

Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer

NCT05876065
recruitingphase_2

A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer

NCT07540533
recruitingphase_3

Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer

NCT05806060
recruitingphase_2

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

NCT06099769
recruitingphase_2

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

NCT05594095
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05876065Not Applicable

Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer

Recruiting
NCT07540533Phase 2

A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer

Recruiting
NCT05806060Phase 3

Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer

Recruiting
NCT06099769Phase 2

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

Recruiting
NCT05594095Phase 2

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Recruiting
NCT03055312Phase 3

Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer

Terminated

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6